Integrated DNA Technologies (IDT) has expanded its portfolio with the new Archer VARIANTPlex lymphoma panel, aimed at advancing blood cancer research.

This tool is designed to detect genetic variations in 49 genes associated with B-cell and T-cell lymphoma, offering researchers a comprehensive profiling solution.

It allows for the detection of single nucleotide variants, insertions, deletions, and copy number variations, providing researchers with a tool that can be used as is, combined with other Archer research panels, or customised to fit specific research needs.

The panel is also designed to work with a variety of sample types, including those that may be low-input or degraded such as formalin-fixed paraffin-embedded (FFPE) tissue.

IDT's latest offering employs anchored multiplex polymerase chain reaction (PCR) chemistry, ensuring compatibility with a wide range of sample types and enhancing the robustness of research outcomes.

The panel can be integrated with the FUSIONPlex lymphoma panel and the IMMUNOVerse BCR panel for a more comprehensive approach to blood cancer profiling.

IDT Archer product vice-president Verity Johnson said: “The development of this panel was driven by our customers’ need for flexible and robust NGS solutions in the blood cancer research space.

“IDT is committed to empowering our customers by providing the tools they need to accelerate the advancement of precision medicine.”

Globally, blood cancer affects around 1.2 million people each year. With the launch of this panel during Blood Cancer Awareness Month this month, IDT reinforces its commitment to the research community in their fight against these diseases.

In March 2020, the company scaled up the manufacturing of a key Covid-19 component for DNA analysis of patient samples.